Atlas Trials

Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma

Clinical trial NCT06441019 · UNKNOWN

Trial details

NCT number
NCT06441019
Sponsor
Fudan University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma,Bispecific Antibodies, HAIC, Ramucirumab
Start date
2024-07-01
Primary completion
2025-05-31
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.